Bleakley Financial Group LLC Makes New Investment in Lantheus Holdings, Inc. $LNTH

Bleakley Financial Group LLC acquired a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 11,583 shares of the medical equipment provider’s stock, valued at approximately $771,000.

A number of other institutional investors have also added to or reduced their stakes in LNTH. Hantz Financial Services Inc. boosted its position in Lantheus by 412.5% in the third quarter. Hantz Financial Services Inc. now owns 492 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 396 shares during the last quarter. Osterweis Capital Management Inc. purchased a new position in shares of Lantheus during the 2nd quarter valued at about $36,000. Farther Finance Advisors LLC raised its stake in Lantheus by 71.4% during the 4th quarter. Farther Finance Advisors LLC now owns 660 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 275 shares during the period. Larson Financial Group LLC raised its stake in Lantheus by 324.5% during the 4th quarter. Larson Financial Group LLC now owns 658 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 503 shares during the period. Finally, Caitong International Asset Management Co. Ltd bought a new stake in Lantheus during the 3rd quarter valued at approximately $55,000. Institutional investors own 99.06% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Weiss Ratings reissued a “hold (c)” rating on shares of Lantheus in a research note on Tuesday. JonesTrading downgraded Lantheus from a “buy” rating to a “hold” rating in a research note on Friday, February 27th. Truist Financial reaffirmed a “buy” rating and set a $115.00 price objective (up from $98.00) on shares of Lantheus in a report on Monday, May 11th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $94.00 price objective on shares of Lantheus in a report on Thursday, May 7th. Finally, Mizuho upped their price objective on Lantheus from $100.00 to $115.00 and gave the stock an “outperform” rating in a report on Wednesday. Eight investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Lantheus has an average rating of “Moderate Buy” and a consensus target price of $101.86.

Lantheus Stock Performance

NASDAQ LNTH opened at $99.30 on Friday. The firm has a market capitalization of $6.47 billion, a P/E ratio of 23.93 and a beta of -0.08. Lantheus Holdings, Inc. has a fifty-two week low of $47.25 and a fifty-two week high of $103.89. The stock has a 50-day simple moving average of $85.66 and a two-hundred day simple moving average of $73.33. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.64 and a current ratio of 2.83.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 EPS for the quarter, topping the consensus estimate of $1.25 by $0.21. The firm had revenue of $377.33 million for the quarter, compared to analyst estimates of $354.48 million. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.Lantheus’s revenue for the quarter was up 1.2% compared to the same quarter last year. During the same period last year, the company earned $1.53 earnings per share. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. On average, equities analysts forecast that Lantheus Holdings, Inc. will post 4.41 earnings per share for the current year.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.